The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $0.16 in the prior trading day, Pieris Pharmaceuticals Inc (NASDAQ: PIRS) closed at $0.14, down -6.60%. In other words, the price has decreased by -$6.60 from its previous closing price. On the day, 1.98 million shares were traded. PIRS stock price reached its highest trading level at $0.1556 during the session, while it also had its lowest trading level at $0.138.
Ratios:
Our goal is to gain a better understanding of PIRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.24 and its Current Ratio is at 3.24. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 14, 2019, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.Robert W. Baird initiated its Outperform rating on May 14, 2019, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 25 ’23 when KIRITSY CHRISTOPHER P bought 10,000 shares for $0.85 per share. The transaction valued at 8,500 led to the insider holds 20,000 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PIRS now has a Market Capitalization of 14345575 and an Enterprise Value of -12020421. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.34 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at -0.281 whereas that against EBITDA is 0.862.
Stock Price History:
The Beta on a monthly basis for PIRS is 0.56, which has changed by -0.8333333 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, PIRS has reached a high of $1.01, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is -16.71%, while the 200-Day Moving Average is calculated to be -34.40%.
Shares Statistics:
The stock has traded on average 638.84K shares per day over the past 3-months and 543650 shares per day over the last 10 days, according to various share statistics. A total of 98.94M shares are outstanding, with a floating share count of 91.57M. Insiders hold about 7.45% of the company’s shares, while institutions hold 38.94% stake in the company. Shares short for PIRS as of 1711584000 were 134126 with a Short Ratio of 0.21, compared to 1709164800 on 70725. Therefore, it implies a Short% of Shares Outstanding of 134126 and a Short% of Float of 0.13999999999999999.
Earnings Estimates
Pieris Pharmaceuticals Inc (PIRS) is currently under the scrutiny of 1 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.12 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.12, while EPS last year was -$0.11. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.35 and -$0.35 for the fiscal current year, implying an average EPS of -$0.35.
Revenue Estimates
1 analysts predict $1.3M in revenue for the current quarter. It ranges from a high estimate of $2.24M to a low estimate of $2.24M. As of the current estimate, Pieris Pharmaceuticals Inc’s year-ago sales were $5.85M, an estimated decrease of -77.80% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.24M, a decrease of -65.50% over than the figure of -$77.80% in the same quarter last year. There is a high estimate of $2.24M for the next quarter, whereas the lowest estimate is $2.24M.
A total of 1 analysts have provided revenue estimates for PIRS’s current fiscal year. The highest revenue estimate was $31.98M, while the lowest revenue estimate was $31.98M, resulting in an average revenue estimate of $42.81M. In the same quarter a year ago, actual revenue was $25.9M, up 65.30% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $6.62M in the next fiscal year. The high estimate is $6.62M and the low estimate is $6.62M. The average revenue growth estimate for next year is down -84.50% from the average revenue estimate for this year.
